Central Serous Chorioretinopathy

Central serous chorioretinopathy (CSC) affects roughly 1 in 10,000 people annually, with men between the ages of 25 and 55 accounting for approximately 85–90% of acute cases (NEI). That demographic skew is striking enough to be diagnostically useful: when a young to middle-aged man reports a sudden blurring of central vision in one eye, CSC belongs near the top of the differential list. The condition involves a detachment of the neurosensory retina from the retinal pigment epithelium (RPE), driven by fluid accumulation beneath the retina — not from a tear or a break, but from dysfunction in the choroid, the vascular layer sitting just behind the RPE.

What Actually Happens in the Eye

The choroid is one of the most richly perfused tissues in the human body. In CSC, the choroidal vasculature becomes hyperpermeabile — abnormally leaky — and the resulting hydrostatic pressure overwhelms the RPE's pumping function. The RPE normally acts as a selective barrier and fluid transport system; when that system is outpaced, fluid pockets beneath the retina, lifting it away from its nutritive base. The result is a dome-shaped blister of fluid visible on optical coherence tomography (OCT), often with one or more focal leakage points identifiable on fluorescein angiography.

Indocyanine green angiography (ICGA) has clarified the pathophysiology considerably, showing that choroidal venous congestion and delayed choroidal arterial filling are consistent early findings (PubMed Central, PMCID: PMC4398968). The choroid in CSC patients tends to be measurably thicker than in unaffected eyes — often exceeding 400 micrometers subfoveally compared to a population average closer to 287 micrometers.

Symptoms and Presentation

The visual disturbance in CSC is characteristically mild relative to its clinical appearance. Patients describe a dim, slightly blurred area in central vision — often with micropsia (objects appearing smaller than they are) or metamorphopsia (distortion of straight lines). Contrast sensitivity drops noticeably, but absolute visual acuity frequently remains 20/40 or better, which can give patients — and occasionally clinicians — a misleading sense of reassurance.

A relative hyperopic shift of 1 to 3 diopters is common, caused by the physical displacement of the retina forward by subretinal fluid. This is one of those quietly revealing details: a patient who suddenly needs reading glasses in one eye warrants a fundus examination.

Risk Factors and Triggers

Endogenous and exogenous corticosteroids are the most consistently implicated risk factor (NIH MedlinePlus). This includes inhaled steroids for asthma, topical nasal steroids, epidural injections, and systemic therapy. The association is strong enough that CSC can develop after even short courses of prednisone in susceptible individuals. The mechanism likely involves corticosteroid receptors in choroidal endothelial cells and alterations in mineralocorticoid signaling — a hypothesis that has driven interest in mineralocorticoid receptor antagonists as therapeutic agents.

Beyond corticosteroids, established risk factors include:

Acute vs. Chronic CSC

The distinction between acute and chronic CSC matters enormously for management. Acute CSC typically resolves spontaneously within 3 to 4 months, with the subretinal fluid reabsorbing and visual acuity returning to baseline in roughly 80% of cases. Watchful waiting is reasonable for the first 3 months when the episode is a first presentation, vision loss is mild, and no corticosteroid use is ongoing.

Chronic CSC — defined by persistence of subretinal fluid beyond 3 to 4 months — carries a more guarded prognosis. Prolonged fluid contact with the outer retina causes progressive photoreceptor attrition. Patients with chronic CSC report subtle but persistent deficits in color discrimination, contrast sensitivity, and low-luminance visual acuity even after the fluid resolves. Approximately 30–50% of CSC cases develop into the chronic form.

Treatment Options

No treatment is universally indicated, but several evidence-based options exist for chronic or visually significant CSC.

Photodynamic therapy (PDT) with verteporfin, particularly at half-dose or half-fluence protocols, targets the dysfunctional choroidal vasculature directly. Half-dose PDT has demonstrated high rates of fluid resolution in randomized trials, with a favorable safety profile compared to standard-dose protocols (ClinicalTrials.gov).

Micropulse laser therapy applies subthreshold laser energy to leakage points without creating visible RPE burns. Evidence supports efficacy in appropriately selected eyes, though head-to-head comparisons with PDT favor PDT for fluid resolution speed.

Mineralocorticoid receptor antagonists — specifically eplerenone (150 mg/day) and spironolactone — have shown statistically significant reductions in subretinal fluid in randomized controlled trials, including the VICI trial published in Ophthalmology (2017). The effect size is modest, but the oral route and low systemic risk make these agents attractive adjuncts.

Anti-VEGF injections, while effective in neovascular AMD, show limited benefit in CSC without concurrent choroidal neovascularization.

Complications and Long-Term Outlook

Choroidal neovascularization (CNV) develops in a subset of chronic CSC patients, particularly those with extensive RPE atrophy. CNV represents a secondary disease process layered onto CSC and may require anti-VEGF therapy independently. Fundus autofluorescence imaging tracks RPE health over time and can reveal the "descending tracks" pattern — a vertical trail of RPE change below the fovea — characteristic of recurrent or longstanding disease.

Bilateral involvement occurs in roughly 15–20% of patients at any given time, though asymmetric presentation is the rule. Recurrence rates over 10 years approach 40–50% in some longitudinal series.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)